Composite measures in psoriatic arthritis: A report from the GRAPPA 2009 Annual Meeting

Journal of Rheumatology

Volumn 38, Issue 3, 2011, Pages 540-545

  Helliwell, Philip S ^a   Fitzgerald, Oliver ^b   Strand, C Vibeke ^c   Mease, Philip J ^d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Outcome measures; Psoriasis; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; COMPOSITE PSORIATIC DISEASE ACTIVITY INDEX; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE 28; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS JOINT ACTIVITY INDEX; PSORIATIC ARTHRITIS RESPONSE CRITERIA; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYMPOSIUM; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ARTHRITIS, PSORIATIC; CONGRESSES AS TOPIC; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952372121     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.101116     Document Type: Conference Paper

References (34)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
2. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
3. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
4. Helliwell PS, Hetthen J, Sokoll K, Green M, Marchesoni A, Lubrano E, et al. Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model. Arthritis Rheum 2000;43:865-71.
5. Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the Disease Activity Score. Br J Rheumatol 1996;35:1101-5.
6. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373-8. (Pubitemid 44620449)
7. Leeb BF, Andel I, Sautner J, Fassl C, Nothnagl T, Rintelen B. The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum 2007;57:256-60. (Pubitemid 47164087)
8. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20. (Pubitemid 127607904)
9. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35. (Pubitemid 38084284)
10. Gladman DD, Tom BD, Mease PJ, Farewell VT. Informing response criteria for psoriatic arthritis. I: Discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 2010;37:1892-7.
11. Gladman DD, Tom BD, Mease PJ, Farewell VT. Informing response criteria for psoriatic arthritis. II: Further considerations and a proposal - the PsA Joint Activity Index. J Rheumatol 2010;37:2559-66.
12. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
13. Coates LC, Cook R, Lee KA, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970-6.
14. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965-9.
15. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167-70. (Pubitemid 46774868)
16. Nell-Duxneuner VP, Stamm TA, Machold KP, Pflugbeil S, Aletaha D, Smolen JS. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546-9.
17. Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Development of a Disease Activity Index for the Assessment of Reactive Arthritis (DAREA). Rheumatology 2000;39:148-55. (Pubitemid 30139347)
18. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
19. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
20. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates L, Veale DJ, et al. Development of a preliminary Composite Disease Activity Index (CDAI) in psoriatic arthritis. Ann Rheum Dis 2010; Epub ahead of print 29 Nov 2010.
21. FitzGerald OM, Helliwell P, Mumtaz A, Coates L, Pedersen R, Molta CT. Application of composite disease activity scores in psoriatic arthritis to the PRESTA dataset [abstract]. Arthritis Rheum 62 Suppl: 514.
22. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed Disease Activity Score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
23. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
24. van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-8.
25. Gladman DD, Landewe R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, et al. Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010;37:453-61.
26. Lindsay K, Ibrahim G, Sokoll K, Tripathi M, Melsom RD, Helliwell PS. The composite DAS Score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. J Clin Rheumatol 2009;15:223-5.
27. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58. (Pubitemid 23223653)
28. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32.
29. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686-91. (Pubitemid 351679544)
30. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009;68:948-53.
31. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6. (Pubitemid 36005790)
32. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998;17:291-6. (Pubitemid 28555135)
33. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. (Pubitemid 10164318)
34. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)